Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Estimation of Advanced Heart Failure With Low Left Ventricular Ejection Fraction and Wide QRS Interval

  • Oh, Changmyung (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Chang, Hyuk-Jae (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Sung, Ji Min (Department of Research Affairs, Yonsei University College of Medicine) ;
  • Kim, Ji Ye (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Yang, Wooin (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Shim, Jiyoung (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Kang, Seok-Min (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Ha, Jongwon (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Rim, Se-Joong (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Chung, Namsik (Department of Internal Medicine, Yonsei University College of Medicine)
  • Published : 2012.10.31
⟨ Previous Next ⟩

Abstract

Background and Objectives: Cardiac resynchronization therapy (CRT) has been known to improve the outcome of advanced heart failure (HF) but is still underutilized in clinical practice. We investigated the prognosis of patients with advanced HF who were suitable for CRT but were treated with conventional strategies. We also developed a risk model to predict mortality to improve the facilitation of CRT. Subjects and Methods: Patients with symptomatic HF with left ventricular ejection fraction ${\leq}35%$ and QRS interval >120 ms were consecutively enrolled at cardiovascular hospital. After excluding those patients who had received device therapy, 239 patients (160 males, mean $67{\pm}11$ years) were eventually recruited. Results: During a follow-up of $308{\pm}236$ days, 56 (23%) patients died. Prior stroke, heart rate >90 bpm, serum Na ${\leq}135$ mEq/L, and serum creatinine ${\geq}1.5$ mg/dL were identified as independent factors using Cox proportional hazards regression. Based on the risk model, points were assigned to each of the risk factors proportional to the regression coefficient, and patients were stratified into three risk groups: low- (0), intermediate- (1-5), and highrisk (>5 points). The 2-year mortality rates of each risk group were 5, 31, and 64 percent, respectively. The C statistic of the risk model was 0.78, and the model was validated in a cohort from a different institution where the C statistic was 0.80. Conclusion: The mortality of patients with advanced HF who were managed conventionally was effectively stratified using a risk model. It may be useful for clinicians to be more proactive about adopting CRT to improve patient prognosis.

Keywords

References

  1. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J 2001;22:1318-27. https://doi.org/10.1053/euhj.2000.2533
  2. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016. https://doi.org/10.1161/CIRCULATIONAHA.109.192064
  3. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter- defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37. https://doi.org/10.1056/NEJMoa043399
  4. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:e1-62. https://doi.org/10.1016/j.jacc.2008.02.032
  5. Cleland JG, Daubert JC, Erdmann E, et al. The CARE-HF Study (CArdiac REsynchronisation in Heart Failure Study): rationale, design and endpoints. Eur J Heart Fail 2001;3:481-9. https://doi.org/10.1016/S1388-9842(01)00176-3
  6. Feldman AM, de Lissovoy G, Bristow MR, et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. J Am Coll Cardiol 2005;46:2311-21. https://doi.org/10.1016/j.jacc.2005.08.033
  7. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50. https://doi.org/10.1056/NEJMoa032423
  8. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003;290:2581-7. https://doi.org/10.1001/jama.290.19.2581
  9. Fonarow GC, Yancy CW, Albert NM, et al. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Circ Heart Fail 2008;1:98-106. https://doi.org/10.1161/CIRCHEARTFAILURE.108.772228
  10. Rassi A Jr, Rassi A, Little WC, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med 2006; 355:799-808. https://doi.org/10.1056/NEJMoa053241
  11. Upadhyay GA, Choudhry NK, Auricchio A, Ruskin J, Singh JP. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol 2008;52:1239-46. https://doi.org/10.1016/j.jacc.2008.06.043
  12. Jarcho JA. Biventricular pacing. N Engl J Med 2006;355:288. https://doi.org/10.1056/NEJMct055185
  13. Curtis AB, Yancy CW, Albert NM, et al. Cardiac resynchronization therapy utilization for heart failure: findings from IMPROVE HF. Am Heart J 2009;158:956-64. https://doi.org/10.1016/j.ahj.2009.10.011
  14. Van Veldhuisen DJ, Maass AH, Priori SG, et al. Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. Eur J Heart Fail 2009;11:1143-51. https://doi.org/10.1093/eurjhf/hfp149
  15. Hays AG, Sacco RL, Rundek T, et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke 2006;37:1715-9. https://doi.org/10.1161/01.STR.0000227121.34717.40
  16. Adams RJ, Chimowitz MI, Alpert JS, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/ American Stroke Association. Circulation 2003;108:1278-90. https://doi.org/10.1161/01.CIR.0000090444.87006.CF
  17. Touze E, Varenne O, Chatellier G, Peyrard S, Rothwell PM, Mas JL. Risk of myocardial infarction and vascular death after transient ischemic at tack and ischemic stroke: a systematic review and meta-analysis. Stroke 2005;36:2748-55. https://doi.org/10.1161/01.STR.0000190118.02275.33
  18. Patel JJ, Whittaker CT. Tachycardia-induced heart failure. Perm J 2007;11:50-2.
  19. Oren RM. Hyponatremia in congestive heart failure. Am J Cardiol 2005; 95(9A):B2-7. https://doi.org/10.1016/S0002-9149(05)00603-X
  20. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004;109:1004-9. https://doi.org/10.1161/01.CIR.0000116764.53225.A9
  21. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69. https://doi.org/10.1161/01.CIR.0000095676.90936.80
  22. Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN; Department of Veterans Affairs Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. QRS duration and mortality in patients with congestive heart failure. Am Heart J 2002;143:1085-91. https://doi.org/10.1067/mhj.2002.122516
  23. Thohan V. Prognostic implications of echocardiography in advanced heart failure. Curr Opin Cardiol 2004;19:238-49. https://doi.org/10.1097/00001573-200405000-00009
  24. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113:1424-33. https://doi.org/10.1161/CIRCULATIONAHA.105.584102
  25. O'Connor CM, Hasselblad V, Mehta RH, et al. Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. J Am Coll Cardiol 2010;55;872-8. https://doi.org/10.1016/j.jacc.2009.08.083

Cited by

  1. Recurrence of Left Ventricular Dysfunction in Patients With Restored Idiopathic Dilated Cardiomyopathy : LV dysfunction in idiopathic DCM vol.37, pp.4, 2012, https://doi.org/10.1002/clc.22243
  2. An Appraisal of Biomarker-Based Risk-Scoring Models in Chronic Heart Failure: Which One Is Best? vol.15, pp.1, 2018, https://doi.org/10.1007/s11897-018-0375-y
  3. Prognostic value of myocardial strain and late gadolinium enhancement on cardiovascular magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy with moderate to severely reduced vol.20, pp.None, 2012, https://doi.org/10.1186/s12968-018-0466-7
  4. Hyponatremia in Heart Failure: Pathogenesis and Management vol.15, pp.4, 2012, https://doi.org/10.2174/1573403x15666190306111812